文献速递炎症性肠病消化道肿瘤与早癌肝病

儿童期起病炎症性肠病的恶性肿瘤与死亡率:ESPGHAN儿童IBD Porto组一项为期3年的前瞻性跨国研究

Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN.
PubMed 文献 · Aliment Pharmacol Ther · 2018-07-08

该研究通过调查在25个国家前瞻性收集42个月内儿童期起病IBD患者发生恶性肿瘤或死亡的信息,纳入IBD诊断后、26岁前发生死亡或恶性肿瘤者。共识别60例患者,包括43例恶性肿瘤和26例死亡(9例死于癌症)。主要死亡原因为恶性肿瘤、IBD或IBD治疗相关非恶性原因(包括感染)及自杀。结论认为恶性肿瘤是主要死亡原因,原发性硬化性胆管炎(PSC)是癌症相关死亡的重要危险因素。

要点

  • 儿童期起病IBD患者中,恶性肿瘤是主要死亡原因,其次为感染。
  • 致命癌症中PSC存在比例为56%(5/9),PSC为癌症相关死亡的重要危险因素。
  • 3例肝脾T细胞淋巴瘤均致命,均未使用生物制剂但曾暴露于硫嘌呤类药物。

核心结论

  • 本研究报道了迄今最大数量的儿童期起病IBD合并癌症和/或致命结局的患者。
  • 恶性肿瘤是主要死亡原因,其次为感染;PSC被确定为癌症相关死亡的重要危险因素。
  • 疾病相关腺癌是比淋巴瘤更常见的死亡原因。

研究设计与样本

  • 前瞻性跨国调查研究,通过调查在25个国家为期42个月收集儿童期起病IBD患者发生恶性肿瘤或死亡的信息。
  • 纳入标准为IBD诊断后、26岁前发生死亡或恶性肿瘤的患者。

主要发现

  • 共识别60例患者,包括43例恶性肿瘤和26例死亡(其中9例死于癌症)。
  • 主要死亡原因:恶性肿瘤(n=9)、IBD或IBD治疗相关非恶性原因(n=10,包括5例感染)、自杀(n=3)。
  • 3例肝脾T细胞淋巴瘤均致命,均未使用生物制剂但曾暴露于硫嘌呤类药物;无其他血液系统恶性肿瘤致命。
  • 其他6例致命癌症包括3例结直肠腺癌和3例胆管癌(CCA)。
  • 致命癌症中5例(56%)存在原发性硬化性胆管炎(PSC)(1例结直肠癌、3例CCA和1例肝脾T细胞淋巴瘤)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease-related inflammation and immune suppression, but data are limited due to their rare occurrence. AIM: To identify and describe the most common causes of mortality, types of cancer and previous or current therapy among children and young adults with paediatric-onset IBD. METHODS: Information on paediatric-onset IBD patients diagnosed with malignancy or mortality was prospectively collected via a survey in 25 countries over a 42-month period. Patients were included if death or malignancy occurred after IBD diagnosis but before the age of 26 years. RESULTS: In total, 60 patients were identified including 43 malignancies and 26 fatal cases (9 due to cancer). Main causes of fatality were malignancies (n = 9), IBD or IBD-therapy related nonmalignant causes (n = 10; including 5 infections), and suicides (n = 3). Three cases, all fatal, of hepatosplenic T-cell lymphoma were identified, all were biologic-naïve but thiopurine-exposed. No other haematological malignancies were fatal. The 6 other fatal cancer cases included 3 colorectal adenocarcinomas and 3 cholangiocarcinomas (CCAs). Primary sclerosing cholangitis (PSC) was present in 5 (56%) fatal cancers (1 colorectal carcinoma, 3 CCAs and 1 hepatosplenic T-cell lymphoma). CONCLUSIONS: We report the largest number of paediatric-onset IBD patients with cancer and/or fatal outcomes to date. Malignancies followed by infections were the major causes of mortality. We identified PSC as a significant risk factor for cancer-associated mortality. Disease-related adenocarcinomas were a commoner cause of death than lymphomas.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Joosse ME, Aardoom MA, Kemos P, et al. Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN. Aliment Pharmacol Ther. 2018. PMID: 29984520. doi:10.1111/apt.14893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。